Pharmacology: p53 activator. Restores wild-type p53 signaling and depletes mutant p53 gain of function.
Induces mutant p53 protein degradation via MDM2 and ubiquitin-proteasome pathway.
Induces p73-dependent cell death in cancer cells without toxicity toward normal cells1
Inhibition of p53-MDM2 interaction remains a viable strategy for cancer therapeutic development2,3
References:
1. S Zhang et al. Cancer Res. 2015 75:3842
2. M Ferraiuolo et al. Front Oncol. 2016 6:77
3. B Hong et al. Curr. Drug Targets 2014 15:80
本公司网站所展示销售的产品仅供科研！
沪公网安备 31011202007337号
